Home Cart 0 Sign in  

[ CAS No. 26759-46-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 26759-46-6
Chemical Structure| 26759-46-6
Structure of 26759-46-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 26759-46-6 ]

Related Doc. of [ 26759-46-6 ]

Alternatived Products of [ 26759-46-6 ]

Product Details of [ 26759-46-6 ]

CAS No. :26759-46-6 MDL No. :MFCD00014904
Formula : C10H13NO4 Boiling Point : -
Linear Structure Formula :- InChI Key :QQFHCCQSCQBKBG-UHFFFAOYSA-N
M.W : 211.21 Pubchem ID :611144
Synonyms :

Calculated chemistry of [ 26759-46-6 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.3
Num. rotatable bonds : 4
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 55.11
TPSA : 70.78 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.46 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.25
Log Po/w (XLOGP3) : 1.59
Log Po/w (WLOGP) : 1.08
Log Po/w (MLOGP) : 0.8
Log Po/w (SILICOS-IT) : 1.05
Consensus Log Po/w : 1.35

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.18
Solubility : 1.39 mg/ml ; 0.00656 mol/l
Class : Soluble
Log S (Ali) : -2.69
Solubility : 0.434 mg/ml ; 0.00205 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.38
Solubility : 0.887 mg/ml ; 0.0042 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.94

Safety of [ 26759-46-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 26759-46-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 26759-46-6 ]
  • Downstream synthetic route of [ 26759-46-6 ]

[ 26759-46-6 ] Synthesis Path-Upstream   1~21

  • 1
  • [ 26759-46-6 ]
  • [ 27631-29-4 ]
Reference: [1] Organic Preparations and Procedures International, 2004, vol. 36, # 4, p. 341 - 345
[2] Organic Preparations and Procedures International, 2004, vol. 36, # 4, p. 341 - 345
[3] Journal of Medicinal Chemistry, 1986, vol. 29, # 5, p. 627 - 629
  • 2
  • [ 26759-46-6 ]
  • [ 50377-49-6 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 1, p. 267 - 276
[2] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 9, p. 846 - 851
[3] Patent: US2013/266563, 2013, A1,
[4] ChemMedChem, 2014, vol. 9, # 7, p. 1476 - 1487
[5] Patent: WO2005/30140, 2005, A2,
  • 3
  • [ 26759-46-6 ]
  • [ 16064-15-6 ]
Reference: [1] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 10, p. 1086 - 1090
[2] Patent: US2016/175453, 2016, A1,
  • 4
  • [ 26759-46-6 ]
  • [ 5653-40-7 ]
Reference: [1] Journal of the American Chemical Society, 1919, vol. 41, p. 2147
[2] Journal of Medicinal Chemistry, 1986, vol. 29, # 5, p. 627 - 629
[3] Journal of Organic Chemistry, 2014, vol. 79, # 23, p. 11339 - 11348
  • 5
  • [ 26759-46-6 ]
  • [ 16712-16-6 ]
  • [ 13794-72-4 ]
YieldReaction ConditionsOperation in experiment
84.7% at 190 - 200℃; for 2 h; Example 1Preparation of 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide (Compound 1)Step 1a. 6,7-Dimethoxyquinazolin-4(3H)-one (Compound 0102); A mixture of methyl 2-amino-4,5-dimethoxybenzoic acid 0101 (2.1 g, 10 mmol), ammonium formate (0.63 g, 10 mmol) and formamide (7 ml) was stirred and heated to 190200° C. for 2 hours. Then the mixture was cooled to room temperature. The precipitate was isolated, washed with water and dried to provide the title compound 0102 as a brown solid (1.8 g, 84.7percent): LCMS: m/z 207[M+1]+; 1HNMR (DMSO) δ 3.87 (s, 3H), 3.89 (s, 3H), 7.12 (s, 1H), 7.43 (s, 1H), 7.97 (s, 1H), 12.08 (bs, 1H).
Reference: [1] Patent: US2009/111772, 2009, A1, . Location in patent: Page/Page column 54; 64
[2] ACS Medicinal Chemistry Letters, 2015, vol. 6, # 10, p. 1086 - 1090
  • 6
  • [ 26759-46-6 ]
  • [ 77287-34-4 ]
  • [ 13794-72-4 ]
YieldReaction ConditionsOperation in experiment
93% at 150℃; for 2 h; Example 1: (Production of 6,7-dimethoxyquinazolin-4-one); Using acetic acid and an inorganic base, ammonia, as a catalyst, 6,7-dimethoxyquinazolin-4-one was produced in the manner mentioned below. 0.84 g (4 mmol) of methyl 4,5-dimethoxyanthranilate, 3.60 g (80 mmol) of formamide, 0.17 g (2.8 mmol) of acetic acid and 0.05 g (2.8 mmol) of ammonia from a pressure cylinder were put into an autoclave of SUS316 having a capacity of 25 mL and equipped with a stirrer, a thermometer and a pressure gauge in a nitrogen atmosphere, and reacted at 150°C for 2 hours. After the reaction, the reaction liquid was cooled to room temperature, and the precipitated crystal was collected by filtration, washed with methanol and then dried in vacuum at 70°C for 2 hours to obtain 0.77 g of a crystal. The obtained crystal was analyzed for the purity by high-performance liquid chromatography, and its purity was 99.5 percent; and 6,7-dimethoxyquinazolin-4-one was obtained at a yield of 93.0 percent. The result is shown in Table 1.
92.1% at 150℃; for 2 h; Example 1: (Production of 6,7-dimethoxyquinazolin-4-one); Using acetic acid and an inorganic base, ammonia, as a catalyst, 6,7-dimethoxyquinazolin-4-one was produced in the manner mentioned below. 0.84 g (4 mmol) of methyl 4,5-dimethoxyanthranilate, 3.60 g (80 mmol) of formamide, 0.17 g (2.8 mmol) of acetic acid and 0.05 g (2.8 mmol) of ammonia from a pressure cylinder were put into an autoclave of SUS316 having a capacity of 25 mL and equipped with a stirrer, a thermometer and a pressure gauge in a nitrogen atmosphere, and reacted at 150°C for 2 hours. After the reaction, the reaction liquid was cooled to room temperature, and the precipitated crystal was collected by filtration, washed with methanol and then dried in vacuum at 70°C for 2 hours to obtain 0.77 g of a crystal. The obtained crystal was analyzed for the purity by high-performance liquid chromatography, and its purity was 99.5 percent; and 6,7-dimethoxyquinazolin-4-one was obtained at a yield of 93.0 percent. The result is shown in Table 1. Examples 2 to 4, and Comparative Examples 1 and 2: (Production of 6,7-dimethoxyquinazolin-4-one); The reaction and the post-treatment were carried out in the same manner as in Example 1, for which, however, the catalyst was changed as in Table 2. In Example 4, ammonium acetate was used as the catalyst; and in Comparative Examples 1 and 2, formic acid or potassium carbonate, respectively, was used alone as the catalyst like in JP-A 2002-338550 (Patent Reference 4). From the results in Table 1, it is known that the reaction system with acetic acid and a base coexisting therein of the present invention gives 6,7-dimethoxyquinazolin-4-one at a higher yield than the conventional reaction system with formic acid or potassium carbonate alone therein.
88.8% at 150℃; for 2 h; Example 1: (Production of 6,7-dimethoxyquinazolin-4-one); Using acetic acid and an inorganic base, ammonia, as a catalyst, 6,7-dimethoxyquinazolin-4-one was produced in the manner mentioned below. 0.84 g (4 mmol) of methyl 4,5-dimethoxyanthranilate, 3.60 g (80 mmol) of formamide, 0.17 g (2.8 mmol) of acetic acid and 0.05 g (2.8 mmol) of ammonia from a pressure cylinder were put into an autoclave of SUS316 having a capacity of 25 mL and equipped with a stirrer, a thermometer and a pressure gauge in a nitrogen atmosphere, and reacted at 150°C for 2 hours. After the reaction, the reaction liquid was cooled to room temperature, and the precipitated crystal was collected by filtration, washed with methanol and then dried in vacuum at 70°C for 2 hours to obtain 0.77 g of a crystal. The obtained crystal was analyzed for the purity by high-performance liquid chromatography, and its purity was 99.5 percent; and 6,7-dimethoxyquinazolin-4-one was obtained at a yield of 93.0 percent. The result is shown in Table 1. Examples 2 to 4, and Comparative Examples 1 and 2: (Production of 6,7-dimethoxyquinazolin-4-one); The reaction and the post-treatment were carried out in the same manner as in Example 1, for which, however, the catalyst was changed as in Table 2. In Example 4, ammonium acetate was used as the catalyst; and in Comparative Examples 1 and 2, formic acid or potassium carbonate, respectively, was used alone as the catalyst like in JP-A 2002-338550 (Patent Reference 4). From the results in Table 1, it is known that the reaction system with acetic acid and a base coexisting therein of the present invention gives 6,7-dimethoxyquinazolin-4-one at a higher yield than the conventional reaction system with formic acid or potassium carbonate alone therein.
87.5% at 150℃; for 2 h; Example 1: (Production of 6,7-dimethoxyquinazolin-4-one); Using acetic acid and an inorganic base, ammonia, as a catalyst, 6,7-dimethoxyquinazolin-4-one was produced in the manner mentioned below. 0.84 g (4 mmol) of methyl 4,5-dimethoxyanthranilate, 3.60 g (80 mmol) of formamide, 0.17 g (2.8 mmol) of acetic acid and 0.05 g (2.8 mmol) of ammonia from a pressure cylinder were put into an autoclave of SUS316 having a capacity of 25 mL and equipped with a stirrer, a thermometer and a pressure gauge in a nitrogen atmosphere, and reacted at 150°C for 2 hours. After the reaction, the reaction liquid was cooled to room temperature, and the precipitated crystal was collected by filtration, washed with methanol and then dried in vacuum at 70°C for 2 hours to obtain 0.77 g of a crystal. The obtained crystal was analyzed for the purity by high-performance liquid chromatography, and its purity was 99.5 percent; and 6,7-dimethoxyquinazolin-4-one was obtained at a yield of 93.0 percent. The result is shown in Table 1. Examples 2 to 4, and Comparative Examples 1 and 2: (Production of 6,7-dimethoxyquinazolin-4-one); The reaction and the post-treatment were carried out in the same manner as in Example 1, for which, however, the catalyst was changed as in Table 2. In Example 4, ammonium acetate was used as the catalyst; and in Comparative Examples 1 and 2, formic acid or potassium carbonate, respectively, was used alone as the catalyst like in JP-A 2002-338550 (Patent Reference 4). From the results in Table 1, it is known that the reaction system with acetic acid and a base coexisting therein of the present invention gives 6,7-dimethoxyquinazolin-4-one at a higher yield than the conventional reaction system with formic acid or potassium carbonate alone therein.
87% at 140℃; for 24 h; 30 g of methyl 2-amino-4,5-dimethoxybenzoate was suspended in 240 ml of formamide, and the system was heated to 140° C. and reacted for 24 hrs. A large amount of solids was precipitated in the flask. The reaction solution was filtered after cooled. The filter cake was washed with a small amount of water and then dried to obtain 29.3 g of the resulting product (87percent).10087] ‘H NMR (400 MHz, DMSO) ö 12.01 (br., 1H), 7.99 (s, 1H), 7.44 (s, 1H), 7.13 (s, 1H), 3.90 (s, 3H), 3.87 (s, 3H)
84.7% at 190 - 200℃; for 2 h; Step 1e.
6,7-Dimethoxyquinazolin-4(3H)-one (Compound 107)
A mixture of compound 106 (2.1 g, 10 mmol), ammonium formate (0.63 g, 10 mmol) and formamide (7 mL) was stirred and heated to 190~200° C. for 2 hours.
The mixture was cooled to room temperature and the resulting precipitate was isolated, washed with water and dried to provide the title compound 107 as a brown solid (1.8 g, 84.7percent): LCMS: 207 [M+1]+; 1H NMR (DMSO-d6); δ 3.87 (s, 3H), 3.89 (s, 3H), 7.12 (s, 1H), 7.43 (s, 1H), 7.97 (s, 1H), 12.08 (bs, 1H).
84.7% at 190 - 200℃; for 2 h; Step 1a.
6,7-Dimethoxyquinazolin-4(3H)-one (Compound 0102)
A mixture of methyl 2-amino-4,5-dimethoxybenzoic acid 0101 (2.1 g, 10 mmol), ammonium formate (0.63 g, 10 mmol) and formamide (7 ml) was stirred and heated to 190~200° C. for 2 hours.
Then the mixture was cooled to room temperature.
The precipitate was isolated, washed with water and dried to provide the title compound 0102 as a brown solid (1.8 g, 84.7percent): LCMS: m/z 207 [M+1]+; 1H-NMR (DMSO.) δ 3.87 (s, 3H), 3.89 (s, 3H), 7.12 (s, 1H), 7.43 (s, 1H), 7.97 (s, 1H), 12.08 (bs, 1H).
78.7% With trichlorophosphate In toluene for 5 h; Reflux In a 100 mL three-necked flask were added 1.5 g (6.2 mmol) of methyl 6-amino-3,4_-dimethoxybenzoate, 3 mL (75.5 mmol) of formamide, 3 mL (32.77 mmol) Oxygen Phosphorus and 25 mL of toluene were mixed and heated to reflux. TLC was carried out for 5 h and the reaction was completed. The mixture was taken out to obtain a brown solid. After adding water, the pH value was neutralized with ammonia water. A precipitate of yellowish brown color was precipitated. : ΕΑ = 5: 1, V / V) to obtain a white flocculent solid 1.2 g, yield 78.7percent, mp: 184-1860C.
67.5% at 150℃; for 2 h; Examples 2 to 4, and Comparative Examples 1 and 2: (Production of 6,7-dimethoxyquinazolin-4-one); The reaction and the post-treatment were carried out in the same manner as in Example 1, for which, however, the catalyst was changed as in Table 2. In Example 4, ammonium acetate was used as the catalyst; and in Comparative Examples 1 and 2, formic acid or potassium carbonate, respectively, was used alone as the catalyst like in JP-A 2002-338550 (Patent Reference 4). From the results in Table 1, it is known that the reaction system with acetic acid and a base coexisting therein of the present invention gives 6,7-dimethoxyquinazolin-4-one at a higher yield than the conventional reaction system with formic acid or potassium carbonate alone therein.
54% at 168 - 170℃; Inert atmosphere A solution of compound 1a (5.0 g, 23.7 mmol) in formamide (50 mL) was heated to 168–170 °C under N2 atmosphere overnight. The reaction mixture was cooled and the resultant precipitate was filtered, washed with water, ether to afford 2 (2.63 g, 54percent) as a beige solid, mp 300–302 °C. 1H NMR (DMSO-d6): d 12.07 (s, 1H), 7.99 (d, J = 3.0 Hz, 1H), 7.44 (s, 1H), 7.13 (s, 1H), 3.91 (s, 3H), 3.87 (s, 3H).
36.4% at 150℃; for 2 h; Examples 2 to 4, and Comparative Examples 1 and 2: (Production of 6,7-dimethoxyquinazolin-4-one); The reaction and the post-treatment were carried out in the same manner as in Example 1, for which, however, the catalyst was changed as in Table 2. In Example 4, ammonium acetate was used as the catalyst; and in Comparative Examples 1 and 2, formic acid or potassium carbonate, respectively, was used alone as the catalyst like in JP-A 2002-338550 (Patent Reference 4). From the results in Table 1, it is known that the reaction system with acetic acid and a base coexisting therein of the present invention gives 6,7-dimethoxyquinazolin-4-one at a higher yield than the conventional reaction system with formic acid or potassium carbonate alone therein.

Reference: [1] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6
[2] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6-7
[3] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6-7
[4] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6-7
[5] Patent: US2016/175453, 2016, A1, . Location in patent: Paragraph 0085; 0086; 0087
[6] Patent: US2009/76044, 2009, A1, . Location in patent: Page/Page column 25-26
[7] Patent: US2009/76022, 2009, A1, . Location in patent: Page/Page column 66
[8] Journal of Medicinal Chemistry, 2010, vol. 53, # 22, p. 8089 - 8103
[9] Journal of Medicinal Chemistry, 2012, vol. 55, # 3, p. 1189 - 1204
[10] Patent: CN105037279, 2017, B, . Location in patent: Paragraph 0049; 0050
[11] Angewandte Chemie - International Edition, 2013, vol. 52, # 33, p. 8551 - 8556[12] Angew. Chem., 2013, vol. 125, # 33, p. 8713 - 8718,6
[13] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6-7
[14] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4455 - 4459
[15] Patent: EP1997812, 2008, A1, . Location in patent: Page/Page column 6-7
[16] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 21, p. 2723 - 2728
[17] Journal of Medicinal Chemistry, 2005, vol. 48, # 5, p. 1359 - 1366
[18] Patent: WO2010/85747, 2010, A1, . Location in patent: Page/Page column 45
[19] MedChemComm, 2014, vol. 5, # 9, p. 1290 - 1296
[20] Bioorganic Chemistry, 2018, vol. 80, p. 433 - 443
  • 7
  • [ 64-18-6 ]
  • [ 26759-46-6 ]
  • [ 77287-34-4 ]
  • [ 13794-72-4 ]
YieldReaction ConditionsOperation in experiment
84.22% at 160℃; for 10 h; To a 250 mL round bottom flask, 2-amino-4,5-dimethoxybenzoic acid methyl ester (20 g, 94.7 mmol), formamide (160 mL), formic acid (4 mL) were added sequentially, and refluxed at 160 ° C for 10 h. The reaction was monitored by TLC (V ethyl acetate: V petroleum ether = 1: 1). The resulting mixture was poured rapidly into ice-water, stirring, standing for a while, solid precipitation, filtration, followed by washing with distilled water (3 X 15mL), washed with ethyl acetate (3 X 15 mL), dried, recrystallized from ethyl acetate and dried to give off-white granular crystals, (16.44 g, 84.22percent).
Reference: [1] Patent: CN104292170, 2016, B, . Location in patent: Paragraph 0189; 0190
  • 8
  • [ 26759-46-6 ]
  • [ 13794-72-4 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2186 - 2192
  • 9
  • [ 75-44-5 ]
  • [ 26759-46-6 ]
  • [ 20197-92-6 ]
Reference: [1] Synthesis, 1981, # 5, p. 391 - 392
  • 10
  • [ 26759-46-6 ]
  • [ 917-61-3 ]
  • [ 20197-92-6 ]
  • [ 28888-44-0 ]
Reference: [1] Organic Preparations and Procedures International, 2004, vol. 36, # 4, p. 341 - 345
  • 11
  • [ 26759-46-6 ]
  • [ 5722-93-0 ]
Reference: [1] Journal of the American Chemical Society, 1942, vol. 64, p. 2983,2985
  • 12
  • [ 26791-93-5 ]
  • [ 26759-46-6 ]
YieldReaction ConditionsOperation in experiment
88.7% With palladium on activated charcoal; hydrogen In methanol at 20℃; for 24 h; 1.9 g (7.2 mmol) of methyl 6-nitro-3,4-trimethoxybenzoate and 0.2 g of palladium on carbon were added into a 100 mL round bottom flask and dissolved in 50 mL of methanol. Hydrogen was introduced and the mixture was stirred at room temperature for 24 h h, TLC detection reaction was completed, a brown solid was removed. Column chromatography (PE: ΕΑ = 10: 1, V / V) isolated and purified to give a white solid 1.51 g, yield 88.7percent, Ke point: 91-93C
72% With hydrogenchloride; tin(II) chloride dihdyrate In water at 0 - 20℃; for 3 h; To a stirred solution of SnCl2*2H2O (30.85 g, 136.7 mmol) in concentrated HCl (100 mL) was added methyl 4,5-dimethoxy-2-nitrobenzoate (10.0 g, 41.4 mmol) portionwise at 0 °C. The reaction mixture was stirred and warmed to room temperature (rt) slowly. After the reaction mixture was stirred at rt for 3 h, it was poured into ice-water, then basified with 6 N NaOH to pH >10. The mixture was extracted with EtOAc, and the combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum. The crude product was purified by column chromatography with EtOAc/hexanes (1:3 to 1:2) to afford 1a (6.28 g, 72percent) as a pale yellow solid, mp 130–132 °C (lit.39 125–128 °C; lit.40 128–133 °C). 1H NMR (CDCl3): d 7.30 (s, 1H), 6.15 (s, 1H), 5.56 (br s, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H).
Reference: [1] Patent: CN105037279, 2017, B, . Location in patent: Paragraph 0047; 0048
[2] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4455 - 4459
[3] Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry, 1995, vol. 34, # 10, p. 911 - 913
[4] Justus Liebigs Annalen der Chemie, 1896, vol. 293, p. 190
[5] Journal of the American Chemical Society, 1919, vol. 41, p. 2147
[6] Journal of Medicinal Chemistry, 1986, vol. 29, # 5, p. 627 - 629
[7] Organic Preparations and Procedures International, 2004, vol. 36, # 4, p. 341 - 345
[8] Patent: WO2010/85747, 2010, A1, . Location in patent: Page/Page column 45
[9] Patent: US3954748, 1976, A,
  • 13
  • [ 2150-38-1 ]
  • [ 26759-46-6 ]
Reference: [1] Journal of Chemical Research, Miniprint, 1980, # 10, p. 4154 - 4171
[2] Organic Preparations and Procedures International, 2004, vol. 36, # 4, p. 341 - 345
[3] Journal of Medicinal Chemistry, 1986, vol. 29, # 5, p. 627 - 629
[4] Justus Liebigs Annalen der Chemie, 1896, vol. 293, p. 190
[5] Patent: CN105037279, 2017, B,
  • 14
  • [ 93-07-2 ]
  • [ 26759-46-6 ]
Reference: [1] Patent: CN105037279, 2017, B,
  • 15
  • [ 67-56-1 ]
  • [ 5653-40-7 ]
  • [ 26759-46-6 ]
Reference: [1] Scientia Pharmaceutica, 2003, vol. 71, # 4, p. 331 - 356
[2] Journal of Organic Chemistry, 2013, vol. 78, # 23, p. 12144 - 12153
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 21, p. 8332 - 8338
  • 16
  • [ 26759-46-6 ]
  • [ 221698-39-1 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 1, p. 267 - 276
  • 17
  • [ 26759-46-6 ]
  • [ 179688-53-0 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 1997, vol. 7, # 21, p. 2723 - 2728
[2] Angewandte Chemie - International Edition, 2013, vol. 52, # 33, p. 8551 - 8556[3] Angew. Chem., 2013, vol. 125, # 33, p. 8713 - 8718,6
[4] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4455 - 4459
[5] Patent: US2009/111772, 2009, A1,
  • 18
  • [ 26759-46-6 ]
  • [ 179688-52-9 ]
Reference: [1] Angewandte Chemie - International Edition, 2013, vol. 52, # 33, p. 8551 - 8556[2] Angew. Chem., 2013, vol. 125, # 33, p. 8713 - 8718,6
[3] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4455 - 4459
[4] Patent: US2009/111772, 2009, A1,
  • 19
  • [ 26759-46-6 ]
  • [ 788136-89-0 ]
Reference: [1] Angewandte Chemie - International Edition, 2013, vol. 52, # 33, p. 8551 - 8556[2] Angew. Chem., 2013, vol. 125, # 33, p. 8713 - 8718,6
  • 20
  • [ 26759-46-6 ]
  • [ 612501-52-7 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 18, p. 4455 - 4459
  • 21
  • [ 26759-46-6 ]
  • [ 1012054-59-9 ]
Reference: [1] Patent: US2009/111772, 2009, A1,
Recommend Products
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 26759-46-6 ]

Aryls

Chemical Structure| 5653-40-7

[ 5653-40-7 ]

2-Amino-4,5-dimethoxybenzoic acid

Similarity: 0.97

Chemical Structure| 2475-80-1

[ 2475-80-1 ]

Methyl 2-amino-5-methoxybenzoate

Similarity: 0.95

Chemical Structure| 50413-30-4

[ 50413-30-4 ]

Methyl 2-amino-4-methoxylbenzoate

Similarity: 0.95

Chemical Structure| 183322-17-0

[ 183322-17-0 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride

Similarity: 0.94

Chemical Structure| 4294-95-5

[ 4294-95-5 ]

2-Amino-4-methoxybenzoic acid

Similarity: 0.92

Ethers

Chemical Structure| 5653-40-7

[ 5653-40-7 ]

2-Amino-4,5-dimethoxybenzoic acid

Similarity: 0.97

Chemical Structure| 2475-80-1

[ 2475-80-1 ]

Methyl 2-amino-5-methoxybenzoate

Similarity: 0.95

Chemical Structure| 50413-30-4

[ 50413-30-4 ]

Methyl 2-amino-4-methoxylbenzoate

Similarity: 0.95

Chemical Structure| 183322-17-0

[ 183322-17-0 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride

Similarity: 0.94

Chemical Structure| 4294-95-5

[ 4294-95-5 ]

2-Amino-4-methoxybenzoic acid

Similarity: 0.92

Esters

Chemical Structure| 2475-80-1

[ 2475-80-1 ]

Methyl 2-amino-5-methoxybenzoate

Similarity: 0.95

Chemical Structure| 50413-30-4

[ 50413-30-4 ]

Methyl 2-amino-4-methoxylbenzoate

Similarity: 0.95

Chemical Structure| 183322-17-0

[ 183322-17-0 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride

Similarity: 0.94

Chemical Structure| 1882-72-0

[ 1882-72-0 ]

Methyl 2-amino-5-hydroxybenzoate

Similarity: 0.92

Chemical Structure| 217314-47-1

[ 217314-47-1 ]

Methyl 3-amino-5-methoxybenzoate

Similarity: 0.90

Amines

Chemical Structure| 5653-40-7

[ 5653-40-7 ]

2-Amino-4,5-dimethoxybenzoic acid

Similarity: 0.97

Chemical Structure| 2475-80-1

[ 2475-80-1 ]

Methyl 2-amino-5-methoxybenzoate

Similarity: 0.95

Chemical Structure| 50413-30-4

[ 50413-30-4 ]

Methyl 2-amino-4-methoxylbenzoate

Similarity: 0.95

Chemical Structure| 183322-17-0

[ 183322-17-0 ]

Ethyl 2-amino-4,5-bis(2-methoxyethoxy)benzoate hydrochloride

Similarity: 0.94

Chemical Structure| 4294-95-5

[ 4294-95-5 ]

2-Amino-4-methoxybenzoic acid

Similarity: 0.92